Podcasts about Roux

In this episode, we welcome legendary sound mixer and CAS President Peter Kurland, CAS. Peter is a BAFTA-winning, Grammy-winning, 4x Oscar-nominated, and 3x CAS Award-winning Sound Mixer who's worked on films such as Blood Simple, Hoosiers, Raising Arizona, Barton Fink, Fargo, Men in Black, The Big Lebowski, O Brother Where Are Thou, The Man Who Wasn't There, Walk The Line, No Country for Old Men, A Serious Man, True Grit, Inside Llewan Davis, and The Tragedy of Macbeth. In our conversation, Peter shares his origin story, about his decades-long collaboration with the Coen Brothers, and stories from capturing sound on set. He also offers insights and advice for the next generation of artists and storytellers today. “The Making Of” is presented by AJA:Butcher Bird Studios solves common video routing and I/O challenges with AJAStep inside Butcher Bird Studios' hybrid production environment with Technical Director Brian Druckman and Executive Producer MeeRa Kim. They explain how KUMO SDI routers and Io 4K Plus help their team deliver flexible routing, low-latency monitoring, and streamlined I/O inside and outside the studio. Read the full interview.Kodak Celebrates Kristen Stewart, Autumn Durald Arkapaw, Joachim Trier and Patricia Keighley at the 8th Annual Kodak Film AwardsChristopher Nolan Presents Inaugural Keighley Award at ASC Clubhouse CeremonyOn March 2, Kodak hosted the 8th Annual Kodak Film Awards at the American Society of Cinematographers (ASC) Clubhouse in Hollywood, honoring filmmakers and artists whose work continues to advance cinematic storytelling on film. 2026 Honorees included: Debut Feature Award: Kristen Stewart (presented by Corey C. Waters, Director of Photography), Lumière Award: Autumn Durald Arkapaw (presented by Vanessa Bendetti, VP and Head of Motion Picture, Kodak), Auteur Award: Joachim Trier (presented by Jason Reitman, Director), Keighley Award: Patricia Keighley of IMAX (presented by Christopher Nolan, Director, Producer and Screenwriter), Music & Commercial Film Director Award: Salomon Ligthelm (presented by Ali Brown, PRETTYBIRD President/Executive Producer), Television Series of the Year: Fallout (presented by Vanessa Bendetti, VP and Head of Motion Picture, Kodak). Read more hereLos Angeles Event: ZEISS Aatma Lenses - A Conversation with Pascale Marin, AFCTuesday, March 10th | Los AngelesJoin ZEISS Cinema at the Showroom for an in-depth discussion and demo of the new ZEISS Aatma cinema lenses. Director Helene de Roux and cinematographer Pascale Marin, AFC will be on hand to discuss their experience using the lenses to craft the short film Welcoming Grace. Join us from 6pm-9pm on March 10th to be one of the first to experience this unique lens family from ZEISS!RSVP for free hereAttendees will receive free parking validation.Now with Massive 8TB Capacity—Thunderbolt 5 SpeedThe OWC Envoy Pro Ultra now comes in a new 8TB capacity, pairing enormous space with next‑generation Thunderbolt 5 performance. With real‑world speeds over 6000 MB/s and a rugged, bus‑powered design, it's perfect for 4K/8K workflows, on‑location shoots, and fast media offloads. High‑speed, high‑capacity, and ready for serious creative work. Browse hereA New Solution from Atomos:The Atomos Shogun AV-19 Rack-Mounted 4K HDR Monitor/Recorder/Switcher is your all-in-one solution for professional live production, combining a stunning 19” 4K HDR DCI-P3 display with quad-channel switching, real-time ISO recording of up to four camera feeds plus program out, and support for 10-bit Apple ProRes, ProRes RAW, and Avid DNx recording to CFexpress or USB-C media. Perfect for studios, video village, and broadcast environments, it delivers the monitoring accuracy and workflow efficiency your production demands. The Atomos Shogun AV-19 is available for pre-order now for $2,099.00. Learn more at Videoguys.com or call our production experts at 800-323-2325 today!Advertise in The Making Of:Feature your products or solutions in The Making Of and reach over 250,000 film and TV industry each week.To explore a partnership, please email mvalinsky@me.comPodcast Rewind:Feb. 2026 - Ep. 122. Get full access to The Making Of at themakingof.substack.com/subscribe

Use "State proofing or maximum appropriate non-cooperation where the State seeks to co-opt ... any non-State actor." That is the advice from Sakeliga CEO Piet le Roux following the latest milestone victory in its fight against the implementation of the NHI Act. "Where the State seeks to co-opt you into an ideological scheme that is clearly harmful, clearly unacceptable, offer the least possible cooperation you can, but do this judicially, do it judiciously, of course," he urges. "There are sometimes risks in not cooperating with the State, but wherever unethical demands that are harmful to society, that are unlawful, that are unconstitutional, are made, I think it's also an ethical duty on people to offer the least possible cooperation." Le Roux describes how useful public interest litigation by Sakeliga and other parties has been. "On all of those cases where we've also achieved good court victories, we have decreased the harms that would have been affected on businesses and on society and on communities, local and nationally."

Tonight's BizNews Briefing opens with Dr Iraj Abedian's view of what could come next in Iran, as he lays out three possible paths ranging from a managed transition to violent instability. We then move to a market update led by MTN's earnings rebound, Exxaro's major manganese deal, the JSE's stronger payout, and pressure on Italtile. Piet le Roux follows with Sakeliga's early legal victory against NHI implementation, before Bloomberg closes on the potentially huge oil implications of a changed Iran-US relationship.

Welcome to the (Not So) New 52, a real-time retrospective of DC Comics' New 52 imprint! Discussed this week: 0:00:00 - Intro 0:03:25 - Grayson #12 (Tim Seeley, Tom King and Mikel Janin) 0:13:39 - Flash #44 (Robert Venditti, Van Jensen and Brett Booth) 0:22:48 - Gotham by Midnight #9 (Ray Fawkes and Juan Ferreyra) 0:33:07 - Deathstroke #10 (Tony S Daniel, James Bonny and Tyler Kirkham) 0:42:32 - Batgirl #44 (Cameron Stewart, Brendan Fletcher and Bengal) 0:52:11 - Sinestro #15 (Cullen Bunn and Ethan Van Sciver) 1:01:11 - We Are Robin #4 (Lee Bermejo and James Harvey) 1:10:53 - Justice League 3001 #4 (Keith Giffen, J.M. DeMatteis and Scott Kolins) 1:21:20 - Harley Quinn / Power Girl #4 (Amanda Conner, Jimmy Palmiotti, Justin Gray and Stéphane Roux, Elliot Fernandez) 1:30:02 - Next Week's Books patreon: https://www.patreon.com/mildfuzztv twitter: @DCComicsPodcast (Use #New52) discord: https://discord.gg/8fbyCehMTy Other Links: https://linktr.ee/mildfuzz Find out more at https://the-not-so-new-52.pinecast.co

Retour sur l’entrevue de Valérie Maltais. Le transfuge Jénéroux se serait fait menacer! Les libéraux sont-ils de retour? Boulerice est-il un néodémocrate ou un solidaire? La rencontre Tougas-Dutrizac avec Stéfanie Tougas. Regardez aussi cette discussion en vidéo via https://www.qub.ca/videos ou en vous abonnant à QUB télé : https://www.tvaplus.ca/qub ou sur la chaîne YouTube QUB https://www.youtube.com/@qub_radioPour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr

Maxime Roux might just be the top up and coming rider for the 2026 season, if you can even say “up and coming”, because Maxime is all but established. Locking down his first PWT win in 2025, Maxime posts nothing but certified heat, and has tricks people dream of on tap. How many riders are doing both switch and regs crow 7s? Maxime is, and they are clean too. We are chatting wakepants, riding in France, first PWT win, La Familia, style vs. steeze, winching, injuries, and so much more. Hear all this and much more in Episode 108 of the Grab Matters podcast with Maxime Roux.Follow Maxime: https://www.instagram.com/roux_maxime/ Follow La Familia: https://www.instagram.com/la.familiaco/Thank you to this shows sponsors! Liquid Force: https://www.liquidforce.com/ Slingshot: https://slingshotsports.com/Support the show: https://www.patreon.com/GrabMattersPodcastChapters:00:00 1:00 Intro1:10 Wakepants started in France…?2:10 Favorite grab3:40 First time riding11:20 Biggest inspo13:00 LF'n Wheel of Questions16:10 First PWT win21:00 Partying with La Familia23:25 Slings Hot Takes27:30 Style vs. steeze30:20 Setup32:10 Being tall38:00 Currently/Social media51:00 Winching55:20 InjuriesLinks:Aspect Mag: https://www.instagram.com/aspectwakemag/?hl=enPizza boi: https://www.youtube.com/watch?v=RFJ_fXwUHfoRoam: https://www.youtube.com/watch?v=qTKrg7kHfcwShoot us a text!Patreon: https://www.patreon.com/GrabMattersPodcastWebsite: https://www.grabmatters.com/YouTube: https://www.youtube.com/@grabmatters/videosInstagram: https://www.instagram.com/grabmatters/TikTok: https://www.tiktok.com/@grabmatterspodcastFacebook: https://www.facebook.com/grabmatters

Send a textIn this final episode of season 18, we sat down with Daniel Wand of Capsize to talk about the band's long-awaited return and the release of their new Under a Hollow Sky EP, out now via Roux & Ruin Records. After years of sporadic single releases, Daniel reflected on why returning to a physical EP format felt essential, allowing the band to tell a complete story for the first time since 2016's A Reintroduction: The Essence Of All That Surrounds Me. We discussed the creative and emotional weight behind tracks like “The Fracture” and the EP's title song, the freedom that came with signing to Roux & Ruin Records, and recently working with producers Matt Good and Cody Stewart. Daniel also opened up about accountability, internal struggle, and maintaining full creative control—both sonically and visually—as Capsize step into a more intentional and fully realized new chapter. So much more to come from these guys.Under A Hollow Sky is out now worldwide via Roux & Ruin Records.Stay connected with Capsize, visit: https://www.instagram.com/capsizeband/ and https://www.facebook.com/capsizeband/Stay connected with IUF, visit: https://interviewunderfire.com/

The crew dives into practical cooking technique: why some induction burners struggle to push a roux dark (and how throttling, pan material, and heat management affect the result), followed by a broader discussion of “high instantaneous heat, low average heat” cooking—rotisserie logic, off-and-on grilling, and moisture control strategies that build crust without overcooking. Dave also revisits shrimp quality—why wild Gulf shrimp taste dramatically better than commodity farmed blocks—and shares recent kitchen experiments, including Austrian scarlet runner beans with pumpkin seed oil and beta-carotene “Golden Fluff-O” biscuit trials. Along the way: New Orleans food notes, po'boy bread realities, and the usual rapid-fire equipment and technique tangents. Hosted on Acast. See acast.com/privacy for more information.

Since the last South African Grand Prix was raced at Kyalami in 1993, the country has made several attempts to bring Formula One back. The circuit has been upgraded to FIA Grade 2 standards, and various promoters, including the Kyalami owners and international partners, have tried to secure a deal with Formula One Management. Most recently, Sports Minister Gayton McKenzie conceded that the 2027 race “will not take place now,” but said government remained committed to landing a future Grand Prix. Anton Roux, a former member of motorsport's governing body, the FIA Senate, and a trustee of the FIA Foundation, says South Africa's real obstacles lie elsewhere, in strained ties with Washington and a lack of political commitment at home. Roux told BizNews that South Africa has not done the diplomatic groundwork needed to convince Liberty Media, the American company that owns Formula One. His advice to the sports minister was blunt: start by backing, and showing up at, the international motorsport events South Africa already hosts, to prove the country can deliver an event that other African nations, like Rwanda, are now openly keen to host. But first, the interview dives into a question many motorheads are asking: Why are electric vehicles so ugly? Is Italian design the answer?

A doctor once asked Amber, at 22 years old, if she wanted to talk to hospice. That gut-punch became a pivot point—not into a fairytale, but into a decade of clear-eyed choices, bariatric surgery, and a long arc of sustainable change. We invited Amber to tell the truth behind the cameras, the clinic, and the countless meals that followed.We walk through what most shows skip: how casting really works, why production often writes your role before it meets you, and what genuine medical prep looks like for Roux-en-Y gastric bypass—therapy, dietitian support, pre-op targets, insurance approvals, and the quiet discipline of a phased, protein-forward recovery. Amber shares why her extreme weight didn't come with expected comorbidities, how subcutaneous versus visceral fat affected her risk, and why assumptions about sleep apnea at larger sizes often miss age and fat distribution. She stayed active at every stage—volleyball, long walks, and now husky-powered jogs—which protected mobility and made progress stick.There's science, but there's also soul. Amber's path wasn't a dramatic drop; it was seasons of plateaus, better sleep, and small, durable wins. We get practical about portions, satiety, and an unexpectedly powerful trick: the “bucket method.” Load your day's food into a visible container or tray and graze with receipts. It's funny, tactile, and radically accountable—a way to keep snacks without slipping into a surplus. Along the way, we trade fiber hacks (chia for the win), talk about gums and fake sauces that taste like a lab, and still make room to laugh at ourselves.Amber is now fundraising for skin-removal surgery, starting with brachioplasty and targeted calf lipo after years of lymphedema and record-size calves that once made walking a grind. Her counsel to anyone struggling is simple and bold: begin with grace, then investigate your why. If overeating props up pain, you can't just yank the beam—you need a new support. Hit play for honesty, nuance, and a plan that favors real life over rigid rules.If this story moved you, follow and share it with someone who needs hope. Subscribe for more candid health, nutrition, and fitness conversations, and leave a review to help others find the show. Support the showYou can find us on social media here:Rob TiktokRob InstagramLiam TiktokLiam Instagram

Antoine Roux est un bootstraper accompli qui a monté son périmètre à plus de 20M€ de chiffre d'affaires. Evoluant sur un marché à plusieurs milliards d'euros à l'année et fort de plus de 80 talents à ses côtés, il nous explique sa roadmap Tech et son envie de croissance externe. Printoclock accompagne de nombreuses PME françaises dans leurs différents besoins de print et Antoine progresse étape par étape dans ce cheminement parfaitement d'autofinancement. Etant lui-même LP dans différents fonds de Venture (Serena Capital et ISAI notamment) et ayant investi plusieurs millions d'euros sur ce segment, il nous partage plusieurs anecdotes croustillantes également au passage.

Welcome, welcome, welcome to the Distraction Pieces Podcast with Scroobius Pip!This week Pip is joined by the Traitors-starring legend JESSIE ROUX!An episode for the books right here! Those of you who love and appreciate the how Traitors will have surely also come to love and appreciate the recent breakout superstar Jessie. Jessie's awesome from the start of course but it's a weirdly rare thing to see and hear folks with a stammer out there in the mainstream media (our very own Pip notwithstanding), so when she comes along and blesses the world with such an aura and pure vibes it is a treat to be celebrated. Naturally - as comes up in the conversation - Jessie is not her stammer, in so much as it is not her identity. So enjoy this brilliant chat which covers so much in her life, upbringing, present day and so much in her personal experience which leads to the person you're listening to in this episode. Pure greatness.* SPOILERS LATE IN THE EP FOR ANYONE WHO HASN'T SEEN SERIES 4 OF TRAITORS AND INTENDS TO!PIP'S PATREON PAGE if you're of a supporting natureINSTAGRAMTRAITORS SERIES 4TRAITORS UNCLOAKEDSTAMMADPP #293 • STAMMA SPECIALDPP #591 • JANE POWELL of STAMMADPP #200 • JESS THOM (Tourettes Hero)PIP AT PRINCE CHARLES CINEMA!SPEECH DEVELOPMENT WEBSTOREPIP TWITCH • (music stuff)PIP INSTAGRAMPIP TWITTERPIP PATREONPIP IMDB Hosted on Acast. See acast.com/privacy for more information.

durée : 00:03:20 - La campagne à Bagnères-de-Bigorre - Le maire sortant de Bagnères-de-Bigorre ne se représente pas. Nicole Darrieutort, sa première adjointe, postule, comme un de ses anciens conseillers municipaux, Gilles Pujo, et le chef de l'opposition, François Roux. Une liste de gauche est portée par Agnès Lazarevitch. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

President Cyril Ramaphosa se verklaring van bek-en-klouseer as nasionale ramp tydens sy staatsrede Donderdagaand is goeie nuus vir Namibië, want dit beteken Suid-Afrika gaan die siekte nou met mag en mening beveg, sê plaaslike landboukenner Wallie Roux. Maar dit beteken geensins Namibië kan laat slaplê nie, het Roux in ‘n onderhoud met Kosmos 94.1 Nuus gesê.

Kea Nonyana from PrimeXBT on Capitec's trading update, falling US unemployment, and claims from US Treasury Secretary Scott Bessent that Chinese speculators are manipulating gold. Maarten Ackerman from Citadel on AI-fuelled US growth and why 2026 could still prove fragile. Willem le Roux of Sanlam Investments Multi-Manager on whether the Sarb can hit a 3% inflation target in 2026.

Wild sort tous les mercredis sur toutes les plateformes ! Suivez nous sur les réseaux sociaux pour connaître toutes nos actualités !Un podcast d'Ambre Gaudet avec Tristan de la Fléchère.Mis en musique et mixé par Morgane PeyrotRetrouvez tous nos podcasts sur maisondupodcast.frUnique Heritage Media / La Maison du Podcast Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Wild sort tous les mercredis sur toutes les plateformes ! Suivez nous sur les réseaux sociaux pour connaître toutes nos actualités !Un podcast d'Ambre Gaudet avec Tristan de la Fléchère.Mis en musique et mixé par Morgane PeyrotRetrouvez tous nos podcasts sur maisondupodcast.frUnique Heritage Media / La Maison du Podcast Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

From washing pots in Cumbria to cooking at The Square, Hof van Cleve and Geranium, and winning the Roux Scholarship along the way, Tom Barnes has taken the long road to the top. In this episode, he reflects on patience, loyalty and why not rushing your career can still lead you to the very highest level. It's a rare, honest look at what two decades in elite kitchens actually teaches you, long before you ever open your own restaurant.That journey now culminates at SKOF, one of only two Michelin-starred restaurants in Manchester. Tom talks about opening the restaurant he always wanted to eat in, celebrating his first star with a no-frills Chinatown Chinese, and designing an experience that feels warm, fast-moving and generous rather than formal or intimidating. From hot broths arriving within minutes to a dining room full of return guests, SKOF is built around instinct, rhythm and pleasure.We get deep into the detail. Why there are three menus. How a 17-course tasting can still feel light and brisk. Why there's no such thing as a filler dish. Tom breaks down blending their own beer, structuring services so guests are never left waiting, and hiding a confit duck leg inside bread because great food should still have moments of joy and surprise.The episode finishes on something deeply personal. Tom shares the story behind Barney's tiramisu, a dessert he still makes exactly as he once did for his dad, now served as a quiet tribute at the end of the meal. Add in football chat, non-alcoholic pairings done properly, hot towels, frozen plates and a city finally getting the food scene it deserves, and this is a conversation that shows how the long way round can be the right way.Pre Order Ben's Incredible Book - All You Can Eat - By Clicking Here - https://www.amazon.co.uk/All-You-Can-Eat-British/dp/1805221523 Hosted on Acast. See acast.com/privacy for more information.

Do you hear that sound? Can you feel it? The cool ocean breeze in your hair, the salt on your tongue. It’s the smooth crash of KVGM “The Last Wave”, with your host, Hammock. A biweekly VGM podcast bringing you the jammiest video game music from all your favorite composers and consoles. Sit back, relax, and get ready to catch…the Last Wave. This week, we’re a little all over the place in energy levels, with morning vibes, afternoon delights, and evening bliss, plus a little reminiscing, hipster bashing, and the Destiny Draw System. Playlist Your Profile~Leaf – Naoya Shimokawa and bermei.inazawa (To Heart, PC) Fresh Prince – ARA (Pri-Pia ~Prince Pia♥Carrot~, Sony PlayStation Portable) Puzzle Editor – BA.M, Einosuke Nagao, Tsuyosi Matsushima, TAISHOW, and SUPERKENTA (Super Nazo Puyo: Rulue no Roux, Super Famicom) AM – Takumu Kotohira (NUKITASHI, PC) Event 4 – Sota Fujimori (Yu-Gi-Oh! 5D's Tag Force 4, Sony PlayStation Portable) Monochrome – Satoshi Okubo (Hotel Dusk: Room 215, Nintendo DS) Jiandia Park Lobby – ASTRO MAN (La Tale, PC) NO PAIN,NO GAIN. – Shigenobu Okawa (Tayutama 2 -After Stories-, Sony PlayStation 4) Headlights on the Shore – Barry “Epoch” Topping (Paradise Killer, Nintendo Switch) Credits – Kazuhiko Uehara (Jikkyou World Soccer 3, Nintendo 64) Special Request In the Night – Motoharu Yoshihira (RAhXEPhON: Sokyu Gensokyoku, Sony PlayStation 2)

*épisode en français* Nail artiste congolo-grecque, Yemo nous parle de son enfance au Congo, de son arrivée en Belgique et le contraste frappant dans la perception de ses cheveux entre les deux pays.

The Murali End gang are joined by former Sri Lanka Coach Anton Roux to preview Sri Lanka at the World Cup. They discuss strengths and weaknesses and how to beat the group stage opposition. Join the Murali End Whatsapp Channel: https://whatsapp.com/channel/0029Val7H91JJhzfMEctCp1P

Avec son nouvel album Happy people, Siân Pottok nous emmène vers la lumière sub-saharienne où jaillit la source de ses racines africaines. Siân Pottok est une musicienne voyageuse, qui a passé une partie de sa vie à arpenter le monde et quoi de plus normal quand on est né d'une mère congolaise et indienne, qu'on a des racines paternelles en Slovaquie et qu'on a grandi entre la Belgique et les États-Unis. Siân Pottok a fait de cette identité plurielle sa marque de fabrique musicale. On l'avait déjà vue à l'œuvre dans son précédent album Deep Waters. « Happy People », son nouvel EP met encore plus en avant ses racines africaines. Siân Pottok y célèbre les échos des ancêtres, à travers le Kamélé Ngoni, cet instrument pour lequel elle a eu une sorte de coup de foudre après y avoir été initié par le bluesman Abou Diarra. ► Titres joués en live : Je danse sur toi et Happy people. ► Chronique : Dans Café Polar, Catherine Fruchon-Toussaint nous parle de Geneviève Roux et son premier roman « Même pas morte » (Stock). En 2018, l'autrice québécoise a survécu à une tentative de féminicide et s'est inspirée de sa propre histoire pour raconter les faits et l'après avec la reconstruction et la quête de justice pour retrouver son agresseur.   ► Playlist du jour : - Siân Pottok - Echoes of the ancestors - Siân Pottok - Shine a light.

durée : 00:05:22 - L'invité d'ICI Matin, ICI Drôme Ardèche - La récolte d'olives vient de s'achever dans le Nyonsais. L'occasion de faire le point avec le président de la coopérative de l'olive de Nyons et vice-président du syndicat de l'olive noire de Nyons, dans la Drôme. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Avec son nouvel album Happy people, Siân Pottok nous emmène vers la lumière sub-saharienne où jaillit la source de ses racines africaines. Siân Pottok est une musicienne voyageuse, qui a passé une partie de sa vie à arpenter le monde et quoi de plus normal quand on est né d'une mère congolaise et indienne, qu'on a des racines paternelles en Slovaquie et qu'on a grandi entre la Belgique et les États-Unis. Siân Pottok a fait de cette identité plurielle sa marque de fabrique musicale. On l'avait déjà vue à l'œuvre dans son précédent album Deep Waters. « Happy People », son nouvel EP met encore plus en avant ses racines africaines. Siân Pottok y célèbre les échos des ancêtres, à travers le Kamélé Ngoni, cet instrument pour lequel elle a eu une sorte de coup de foudre après y avoir été initié par le bluesman Abou Diarra. ► Titres joués en live : Je danse sur toi et Happy people. ► Chronique : Dans Café Polar, Catherine Fruchon-Toussaint nous parle de Geneviève Roux et son premier roman « Même pas morte » (Stock). En 2018, l'autrice québécoise a survécu à une tentative de féminicide et s'est inspirée de sa propre histoire pour raconter les faits et l'après avec la reconstruction et la quête de justice pour retrouver son agresseur.   ► Playlist du jour : - Siân Pottok - Echoes of the ancestors - Siân Pottok - Shine a light.

John Steenhuisen – minister van landbou & Piet le Roux – uitvoerende hoof, Sakeliga. Volg RSG Geldsake op Twitter

In this episode of BizNews Daybreak for Tuesday, 27 January 2026: Markets Rally: The Rand strengthens overnight below the critical R16/$ level, while Gold opens the day above a record $5,000/oz, driving massive gains for JSE miners. The FMD Crisis: A dairy farmer and Sakeliga CEO, Piet le Roux, expose how the state is allegedly "blocking solutions" to the Foot-and-Mouth epidemic, forcing businesses to intervene in a "systemic failure." Trump's Trade War: The US President slaps surprise 25% tariffs on South Korea and makes a historic $1.6bn direct investment into Rare Earths to counter China. Survival Story: Rusty Labuschagne recounts the harrowing nightmare of spending 10 years in Zimbabwean prisons for a crime he didn't commit. Hosted by Alec Hogg.

Costumes Savez-vous que la teinture végétale peut transformer non seulement les tissus, mais aussi notre manière d'appréhender la mode et l'écologie ? Dans cet épisode captivant d'ArtEcoVert La voix de la couleur végétale et des plantes tinctoriales, Pauline Leroux, ingénieure agronome passionnée de couleur végétale, reçoit Ludivine Roux, une spécialiste reconnue de la teinture végétale et du costume. Ensemble, elles plongent au cœur des nuances fascinantes que peuvent offrir les plantes tinctoriales, tout en abordant les enjeux écologiques qui en découlent. Ludivine partage avec enthousiasme son parcours, de sa formation à l'ENSAT à ses expériences enrichissantes au sein de productions cinématographiques. Grâce à son expertise, elle nous dévoile comment la couleur végétale est essentielle pour créer des costumes authentiques qui racontent une histoire tout en respectant notre planète. En effet, la teinture végétale ne se limite pas à une simple palette de couleurs, elle est un véritable engagement envers un avenir durable. Dans cet épisode, Pauline et Ludivine discutent des défis et des techniques de patine, des méthodes respectueuses de l'environnement qui permettent de sublimer les costumes tout en minimisant l'impact écologique. Ludivine insiste sur l'importance de sensibiliser les créateurs de costumes à l'utilisation de teintures végétales, un savoir-faire qui mérite d'être transmis et valorisé. Comment peut-on encourager cette démarche auprès des professionnels du secteur ? Ce dialogue riche en enseignements met également en lumière la collaboration entre les acteurs du costume et la nécessité d'une formation continue sur la teinture végétale. Quels projets futurs se dessinent pour promouvoir cette pratique ? Ludivine et Pauline partagent leurs visions et aspirations, offrant un aperçu inspirant des évolutions à venir dans le domaine de la teinture végétale. Ne manquez pas cette occasion d'en apprendre davantage sur l'univers de la couleur végétale et des plantes tinctoriales ! Que vous soyez passionné par la mode, l'écologie ou simplement curieux d'explorer de nouvelles perspectives, cet épisode d'ArtEcoVert La voix de la couleur végétale et des plantes tinctoriales vous apportera des clés essentielles pour comprendre l'importance de ces pratiques durables. Pour approfondir vos connaissances, n'hésitez pas à consulter les liens utiles mentionnés dans l'épisode. Belle écoute ! ArtEcoVert informe et inspire celles et ceux qui veulent repenser la couleur autrement, et les accompagne dans leur transition vers une couleur plus durable — avec des témoignages concrets le jeudi

Piet le Roux, uitvoerende hoof van Sakeliga, bespreek die agtergrond en jongste verwikkelinge in die Ekurhuleni-saak oor onteiening sonder vergoeding en soortgelyke gevalle. Volg RSG Geldsake op Twitter

Suid-Afrikaanse sanger en liedjieskrywer Roux is die man agter vele bekende liedjies soos ‘Tekkies Brand', ‘Bietjie Benoni' en ‘Vuil Coke', en nou neem hy weer sy plek in die kollig in met nuwe musiek. Na jare waarin Roux treffers vir ander kunstenaars geskryf het, het hy besluit dit is weer tyd om self in die kollig te tree, en in 2025 het hy 'n nuwe album, ‘Al Lankal', sowel as nuwe enkelsnitte vrygestel. As deel van sy terugkeer na die kollig het Roux die jaar afgeskop met die heel eerste Friday Live-optrede van 2026.

HEY GUYS! This week: Isaac eats from the healthy side of the KFC menu, More Cruise Stories, Partying, Getting Drugs Mixed Up, Pantera Sara, Picking Stuff Up Easily, Optic Printer, Hacks, Trump Didnt Get Shot, Diet Culture, and Watches - ENJOY! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Entrevista Laura Alemán y Marcelo Roux - Parque Mauá se inauguró en predio de la ex Compañía del Gas by En Perspectiva

After 128 programs in 2023, our podcast of the year goes to Sofie Roux. Sofie is 19 years old and is wise for her age. Sofie has a "condition of the heart" that started with helping students in Malawi. How can a person use the tools they have to help others, especially those without electricity and basic needs? Sofie poses the question- how can we create and innovate to help the future world, especially for young women? Perhaps being significant starts with a design mentality. Learn more about Bloombox Designs. at www.bloomboxdesignlabs.com.Become a supporter of this podcast: https://www.spreaker.com/podcast/success-made-to-last-legends--4302039/support.

Retatrutide is years away from FDA approval and yet the fight over access, price, control of this medication is already well underway. That's what this podcast is going to be about today. There's well over a hundred thousand people by my estimates who are already on some form of this medication today. And that should tell you enough about how disruptive this molecule is and will be. It is a game changer among game changer. We've been talking about it for three years here at On The Pen, well before any of your favorite gym bros were talking about Retatrutide. We were talking about Reta, who tried Retatrutide here at On The Pen. And that's because we identified this triple agonist as a game changer among game changers. So This is going to be a very Retatrutide heavy episode, and so I hope you'll join us and stick with us if this is a topic you enjoy, because I think this is really going to effectively lay the groundwork for what accessibility to this medication will look like. So let's get into it. Welcome to the On The Pen Podcast with your host, Dave Knapp. Welcome to the On The Pen, the weekly dose podcast. This is our weekly roundup in incretin memetic news. And frankly, there's no news that is bigger than Reta-Trutide news. Just find me any news that is bigger than the data that we got on Reta-Trutide. Now, we already did a video about the Triumph Phase II clinical trials that we got in osteoarthritis of the knee. You can go back and check out that video if you'd like more data. So we're not gonna super... rehash the data. We'll go over at a high level what the data showed us. We're not going to go over how the medicine works, because by now we all know that it's the triple agonist, right? If terzapatide was a dual agonist, GLP-GIP, Retatrutide is the triple agonist that adds to it a glucagon component, which is absolutely just shredding, shredding liver fat. It is absolutely revving up people's metabolism and showing a tremendous amount of weight loss. So let's get into what the weight loss looked like in this first trial, because there are longer obesity trials where, where the primary outcome is the weight loss this was again a specific trial in measuring pain reduction in folks with osteoarthritis of the knee but check out these numbers these are placebo adjusted meaning it's taking the two percent out that people lost on placebo but looking at these numbers Folks on one milligram over forty eight weeks lost seventeen percent. They bumped up to four milligrams. Those folks lost twenty two percent. So right there at the lowest dose, you're already reaching the efficacy of today's drugs that are on the market, like triseptide and semaglutide in their various forms. If you bumped up to eight milligrams, you saw twenty four percent placebo adjusted weight loss and at twelve milligrams, twenty six point four percent weight loss. Adding back in that two percent of the placebo that those on placebo loss, that's twenty eight point four percent weight loss in these forty eight weeks at the highest dose. When you adjust for some of the more real world outcomes, you kind of ding the numbers a little bit based upon people who quit the drug, et cetera. Those numbers look more like a twenty percent weight loss and twenty three point seven percent weight loss at the highest dose. But even then, you're still seeing a drug that is better than the current drugs that are on the market. around forty eight percent of patients on Retatrutide lost greater than twenty five percent. And then if you were at that twelve twelve milligram dose, that highest dose patients lost fifty nine percent of patients lost more than twenty five percent of their body weight. There was a subset that lost thirty percent of their body weight and some even over thirty five percent of their body weight on Retatrutide. So the lower doses compete with today's best drugs and the upper doses are entering into bariatric surgery level weight loss. And that's putting the whole obesity system on notice and probably a lot of surgeons nervous because typical body weight loss was something like the street sleeve gastrectomy. For example, it's about eighteen to twenty five percent body weight. The Roux-en-Y gastric bypass twenty five to thirty five percent weight loss or the duodenal switch thirty to forty percent weight loss. So the upper doses of Ritutrutide overlap with sleeve and bypass outcomes without any surgery. It's incredible. It is a game changer among game changer. It is the new benchmark in obesity medicine. And there's actually more data, like I said, landing in later twenty twenty six. The longer duration will historically, if history is a marker, equal more weight loss than we even see here at this forty eight weeks. We have an interview that will be airing later this week on our channel and on our podcast with our friend Mimi from Australia who just wrapped up her clinical trial on Retatrutide. They ended it like ten weeks early on her, which was a huge bummer to her. So we're going to hear from her because she had to end abruptly. We're going to hear her story, an incredible story. She's one of those folks that got up that thirty five percent body weight loss in the time that she was on Retatrutide. So, this is just showing you that these drugs are not simply an alternative to bariatric surgery. We are approaching a point in time where these are on par with bariatric surgery, and as people are on this Reta-Trutide trial, you see that these numbers aren't plateauing either. So we will see stronger weight loss numbers the longer that these folks are on this trial. And I think you'll see some of those numbers in that population of folks on the higher doses eclipse maybe even some of what we see with some of these bariatric surgeries. the real story that i think is taking shape here is not in how powerful Retatrutide is because we've literally been expecting or anticipating this kind of data for more than three years at on the pin we've been talking about this and i think that's sort of reflected in the fact that you didn't see this massive spike in eli lilly stock wall street was expecting this as well Um, so it was on par, I think with expectations, but the expectations are astronomical compared to previous options that were available to patients and all the innovation in the world. All of these drugs, we talked at last week about WV, E double Oh seven, the James Bond of weight loss that targets fat, not only targets fat loss, but it also targets the promotion of building of, of lean muscle mass. We're talking about an insane future in obesity medicine. But none of it means anything if people can't access it. And that's really where we are today in terms of ensuring that there's going to be an option for everyone. And that's sort of what I want to get into today, because Lilly wants Retatrutide to be classified as a biologic, so not a traditional small molecule drug like you've seen every other incretin and nutrient-stimulated hormone-treating obesity on the market to date. They're trying to get this classified as a biologic. Now, we talked about this before on the podcast. That matters in three major ways. It affects the exclusivity length of time that a pharmaceutical company has on a drug. That goes from, I believe, five years of market exclusivity to twelve. It affects compounding rules because biologics cannot be compounded. And then that gives the pharmaceutical companies a tremendous amount of pricing power in the marketplace, because essentially there's no competition and there's no competition for a long time. But this whole argument about getting this classified as a biologic is not about safety. It's about protection and we're going to get into it. So let's explain this here. This is why Retatrutide really is not a biologic arguably. So biologics are large proteins. There are hundreds of or even thousands of amino acids grown in living cells that are sensitive to tiny manufacturing changes. Retatrutide is a short chain peptide. It's chemically synthesized and it is below the traditional biological size thresholds when it comes to how those things are defined. We'll just leave it at that. So even though it acts like a biologic in the body, it's made like a drug. It's made like a small molecule drug. And if it's treated as a drug, they get, like I said, five years of market exclusivity. Now, really a lot of confusion around what this means, but essentially the first five years of the life of a drug, the patent can be challenged for a number of reasons. We've seen patent challenges right now are going on in the courts for both semaglutide and terzepatide. But these companies are guaranteed that five years of market exclusivity, no matter how those patent lawsuits shake out. That five years jumps to twelve years with the biologic. So ultimately, there's no biosimilars that are allowed during that twelve year window. Again, with terzapatidin and semaglutide, it's five years. They could lose their market exclusivity within five years of the release of the patent. twelve years with a biologic. So if they lose their patent challenges on Trezabitide, they still have some time left with market exclusivity for the drug. They likely will not lose those, but that jumps to twelve years. And I think the most important thing to understand about the reclassification of Reta-Trutide to a biologic would mean that, 503A and 503B pharmacies are effectively locked out of compounding this medication, 503Bs would have some latitude arguably, but they would face extreme barriers. Routine compounding becomes legally and technically restricted because biological status doesn't slow compounding down. It actually shuts the door or almost completely shuts the door. Biologics not only would allow Lilly to have longer market exclusivity, no compounding, but it would allow them to command a higher price in the marketplace because A, they get this designation and there's an assumption when they bring this to market that they're harder to manufacture, that they're harder to copy, that there are fewer negotiating alternatives for payers. They can command a higher price with the insurance companies, and the price pressure stays muted for much longer because, again, you don't have those pressures of compounding. You don't have the pressures externally from lawsuits that could end your market exclusivity in that first five years of the drug's existence. So there's just a lot of price pressure upwards on a biologic compared to a normal small molecule drug. And when there's no credible alternative or backup option, which to Retatrutide, there wouldn't be, it'd be the first drug that has bariatric surgery level results. The prices won't come down. They'll command a massive price and the prices won't come down. So let's talk about where this currently stands because ultimately the Eli Lilly went to the FDA. We've been covering this for well over a year, maybe close to two years now, a year and a half at least. Lily went to the FDA, they said, we want this classified as a biologic, here are the reasons why. The FDA initially said, no, we're not gonna do that. So Lily challenged that decision in court. So the point that we're at today is the court told the FDA to reconsider and better explain itself So the first no given to the FDA to Lilly didn't stick. The courts looked at it and they said, you need a better, you need to reconsider your decision and you need to explain your decision better to Lilly. So ultimately we're sitting now at the point where the court has made its decision that the FDA has to go back and now we await basically what the FDA has to say on this. But if this thing is classified as a biologic, that would be a massive massive loss for patients. Now, again, we're, we're focusing on the accessibility of this drug into the future. And, and I think that this is an important conversation to have. One of the interesting points that I have to bring into the conversation is the fact that I got to sit in on a, on a closed session question and answer with the media. I didn't get to answer or, excuse me, excuse me, ask a question at this time, but shortly after the most favored nations announcement, with eli lilly and the trump administration in the oval office that day there was a press briefing that i was invited to dave ricks was asked by max bayer reporter of endpoints who we've interviewed here on this very podcast and he was asked was Retatrutide included in the most favored nations discussions meaning will we get a cash pay version of Retatrutide uh that is you know circumventing the pbms uh will we get these cheaper prices will will it be be two hundred fifty dollars also and there was a hard no there was a hard no like no that was not included that was not part of these discussions even though what we heard from the trump administration was that those these companies that were jumping on to the most favored nations agreement were also agreeing to offer future drugs at most favored nations pricing now was lily saying that no they're not going to offer it at the it wasn't part of the negotiations in terms of the price points that they had discussed for triseptide maybe or did it mean altogether there won't be a cash pay option of this medication i don't know um that we would love to get clarity on But I highly doubt we're going to get any more information than necessary at this point in time. So, Reta-Trutide is being positioned to be a drug that, and well so, should be offered at a premium. This is a drug that is far exceeding the current drugs that are on the market. I think that we're gonna see even the indications of Reta-Trutide far beyond simple obesity, but it is going to be their crown jewel for the next decade, more than likely. Reta-Trutide is going to be a massive drug, and so they're attempting to build a moat around it. And these are things that we need to be aware of as a community so that we can hold our positions and conversations about these and basically, you know, be able to articulate to people in positions of power like this is an important thing to us. This is an important thing in the advocacy of obesity and sort of the next frontier of the fight of accessibility, which marches on. each and every day because of course the current drugs, while as great as they are and as much as access is expanding, there are still people with sicker or rather more advanced versions of metabolic disease that are gonna need these newer treatments and price is going to be a huge factor. So let's talk about the gray market right now because I think it's also nearly impossible to talk about this topic without including a discussion about the gray market because there are, as I mentioned at the outset, hundreds of thousands of people on this medication already. So research grade Retatrutide exists. It's in the gray markets of the Internet. It's where people are going and they're buying, you know, basically versions of these these peptides that are made in factories overseas. They're being imported into the United States, oftentimes illicitly in shipments that are marked as something else. The FDA has tried to crack down. There's no doctor involved in this. It's a very, that's why it's called the gray market, right? So it's not a prescription medicine, but the demand for this is massive. And all you have to do is really scroll your TikTok for about fifteen minutes. You're going to come across a insane amount of content on the topic of Retatrutide. An insane amount of, and oftentimes, you know, what I find most disturbing is oftentimes it looks like very young people. very young people taking Retatrutide. Crazy, it's crazy. But the demand is massive and there's a whole gray market for it proliferating over on TikTok and in the far reaches of the internet. And I would estimate that tens, if not hundreds of thousands of people are already or have already used it. And I think it's a testament to a to to the effectiveness of this drug. It's also a testament to the fact that there needs to be more guardrails, I think, around this stuff than there currently is, because gray markets appear and they thrive when legal access lags the reality of the demand for the medication. And you saw this earlier this week as we launched a petition to fight back against the Safe Drug Act of twenty twenty five, a drug, a drug act that is in theory designed to put guardrails around compounding. But in practice, I think is creating a new battlefield for Eli Lilly and Novo Nordisk to shut down compounding on the current classes of medications, which is why We as a community need to be loud about our opposition to it. If they were really concerned about the safety of compounds, they would do two very simple things. They would require reporting around the active pharmaceutical ingredient of a compound. Patients ought to be able to know where the actual source of their medication is coming from. And they should know that those places are FDA approved and inspected. And the second thing is they should require adverse event reporting. Those are required of 503Bs. They should be required of 503As as well. 503As are making a tremendous amount of money. They're making thousands and thousands of these scripts. So when there are adverse events, they should be required to report those to the FDA. Simple. None of that is in this bill. None of it. None of it. Instead, it seeks to put caps on the amount of compounds that can be made by a compound pharmacy without them having to report to the FDA. And then it seeks to codify the definition of essential copy. Again, all of these things that will become law and then argued in court and then a battlefield for Lilly to potentially win a legal battle and thwart compounding. It's creating a new battlefield for them. They're losing in the courts. They're losing with the current language that exists in the Food, Drug, and Cosmetic Act. So we create new language. We create new law. Just vague enough to pull some threads and hopefully win something in court. That's how I see it. You may see it differently. If you do, curious to hear from you. But if you want to fight back against this legislation, you can go to otplinks.com and fight back against that. piece of legislation, because I think that we need as a community to have our voices heard on this, especially those who have gotten healthier by way of compounded medications. So the rumor on the gray market, to get back and close the thought loop here, There's been no specific FDA cutoff announced, but what the rumors going around are that that the compounded versions of GLP ones, especially obesity medicine in the gray market, are all going to turn off like a sieve on January first. Now, I seem to feel like this is probably more of a marketing tactic by these companies to sell a whole bunch of peptides at the end of the year. I think that's probably creating some panic and probably panic buying on people's parts. And so these companies are benefiting greatly. Again, that's why there should be guardrails around this. There's no guardrails around this at all. I mean, at the end of the day, they can say whatever they want to say, so long as they cloak everything in research grade. And these rumors proliferate around and people spend thousands, tens of thousands of dollars. I've heard of people having twenty years worth of Retatrutide in their freezer. Why? For what purpose do you need that? So just a massive amount of money made in this gray market. And that's not to knock people who use it. I say this all the time, but I think it's worth qualifying the statement. It's not knocking people who use it. I get it. But at the same time, we're talking about an industry that is, there's no altruism here. They're in it for money just as much as Eli Lilly is, except they have actually done nothing in the way of advancing medicine. They've just taken intellectual property, copied it, and sold it to you with a label that says, don't put this in your body. So you know where I stand on the gray market. I've heard from many people who've been injured by gray market stuff. It's just what it is. It's a gray market. You're taking your health into your own hands. Please, whatever you're doing out there, as risky as it may be, please involve your doctor and let your doctor know what you're doing so you can be monitored for the things your doctor believes you should be monitored for if you're using this. But this all underscores, again, the need for accessibility to these medications, the need for us to be aware of the fact that a moat is already being built around the most advanced metabolic drug in the pipeline. And we just need to be aware so that when it comes time to fight, we're all ready and informed. And that's what this podcast is serving to do. Before we jump into the next topic, I do want to thank our sponsor, our headline sponsor of this podcast. is a company called Shed. Now, if you are looking for access to care for obesity, then look no further than our partners at Shed who believed in this podcast enough to help us do it full time. You can go to Trished.com and use code OTP25 to save twenty five percent at Trished.com, where you're going to get connected to a doctor who will when medically necessary prescribe medication to treat your obesity. You also get access to coaching. You'll get access to all sorts of medication, whether it's the branded or the compounded versions, depending on your specific situation. All of it is available at Trished.com. They use one of my favorite compound pharmacies in the game, Strive Pharmacy, which I've gotten the chance to dig into on my own. I really love what they do there. They're a It functionally operates a lot more like a 503B. Uh, and I think that they're doing great work over at a strive pharmacy. They partner with shed. So I just love this, this, and when we were looking for somebody to offer a compounded versions, I wanted to make sure that I trusted the pharmacy. People always ask me, Dave, who, who should I go to? I'm like the pharmacy matters more than anything because you want to trust the source of your medication. So try shed.com use code OTP25. Listen, you're going to want to learn about taking any new medication before you take it. Learn about the potential side effects. Learn about the trade offs. There's no free lunch, but all of the information that you're going to need, you can find it. Try shed.com and be familiarizing yourself with all of your options there. So thank you to Shed for being a wonderful partner here at On The Pen. Now let's talk about some data that dropped. We're talking about accessibility and all of the sort of advancements in the world mean very little if people can't access it. That's why I think this data that dropped this past week from our friends over at Rowe is incredible. Absolutely game changing data. So check out this data. Real world telehealth data looking at sixty eight weeks. This is looking at patients who were enrolled in their row body program and on a GLP one specifically some maglutide mean weight loss in this study looked at again patients in over sixty eight weeks. The mean weight loss was sixteen point six percent on average. Thirty three percent of patients lost more than twenty percent and the safety in this study and looking at this data match the clinical trials. So what we're seeing here is that care for obesity can be delivered through a telehealth platform at scale and match clinical trial results. So that scalability decides how many people get access. There are not enough doctors out there to serve the over hundred million people in the United States living with overweight or obesity. so when you hear these blowhard doctors online calling all telehealth platforms except their own a pill mill or as i like to say pin mill the data is actually showing something quite different in that this type of obesity care can be delivered at scale through telehealth platforms it can meet people where they're at and allow people to get care without the shame, without the stigma, without their doctor just pointing to the door and saying, if you want a GLP-I, get out of my office. I ain't going to get it here. How ridiculous. But these people can go to platforms like Rho or Shed or any number of telehealth platforms that are out there and not only get access to medicine, but get access to care. So of course, not all telehealth companies are created equal. Of course, not all compound pharmacies are created equal. You want to do your homework and all of that. But this is data that shows that This kind of care can be delivered at scale via a virtual platform and show similar results to a clinical trial. I think, and this is peer reviewed data, and I think that this is just absolutely great news because when we talk about the problem, we need scalable solutions. The old brick and mortar ain't going to work when you don't have enough doctors to serve enough patients. If we want to get life-changing treatments like ritatratide or terzapatide, semaglutide, whatever, into the hands of the people who need it the most, we need companies to innovate scalable tech platforms that can meet patients where they are, that can leverage current technologies to find people the care that they need. And in this case, it's access to a doctor. It's access to a platform. It's access to prescription medication when appropriately prescribed. And it can be done, and it is being done. So I think this is great news, and will play a huge part in the future. As we talk about Retatrutide, even though it's a year and a half away, maybe a little bit longer, it's already exposing – the issues around accessibility and pricing. Hopefully there will be compounded versions available if they're medically necessitated, if there are shortages. We hope that the battleground for that is not already set and won by Lilly before this drug even comes to market. But there are strategies being done to keep people boxed out But I can tell you that whatever happens with Retatrutide, the future of obesity medicine is in virtual care. And platforms are rising to the occasion. Retatrutide hasn't reached patients yet, but it's already forcing the system to show us, you know, are you ready? Are you ready to deliver bariatric surgery level results at scale to the people who need them? So I am so thankful that you joined me here on this podcast today. Again, we love to talk about we're at a Retatrutide. If you're interested, we've been going live every Monday, Wednesday and Friday at eleven a.m. Central Time here on our YouTube channel, on our tick tock, on our X platform. We're doing that because there's enough news to bring you just about every single day. And we've been doing it for the last couple of weeks. If you've enjoyed it, let me know in the comments of the video on YouTube. Send me an email at David on the pen dot com. Uh, so every single Monday, Wednesday, Friday, and then we do a weekly rundown of the obesity medicine news every Tuesday. That's what this is. The weekly dose podcast. You can catch this on all of the platforms that you listen to your podcasts on, and please make sure to leave us a five star rating and review before you log out of your podcast app. That helps so much. I don't think you guys understand how much that helps, uh, the work that we do here to just train the podcast algorithms that this one is worth listening to. I hope you enjoyed today's podcast. If you did, drop it a thumbs up, five-star review, subscribe on YouTube, do all the things. Thank you for being here, and thank you for being the best part of what we do. We will catch you on the next one. Thank you, my friends. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Zain Johnson speaks to Marlene le Roux, CEO of Artscape Theatre, about the latest productions, performances and upcoming highlights at the Artscape. Weekend Breakfast with Sara-Jayne Makwala King is the weekend breakfast show on CapeTalk. This 3-hour morning programme is the perfect (and perky!) way to kickstart your weekend. Author and journalist Sara-Jayne Makwala-King spends 3 hours interviewing a variety of guests about all things cultural and entertaining. The team keeps an eye on weekend news stories, but the focus remains on relaxation and restoration. Favourites include the weekly wellness check-in on Saturdays at 7:35 am and heartfelt chats during the Sunday 9 am profile interview. Listen live on Primedia+ Saturdays and Sundays between 07:00 and 10:00 am (SA Time) to Weekend Breakfast with Sara-Jayne Makwala-King broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/AgPbZi9 or find all the catch-up podcasts here https://buff.ly/j1EhEkZ Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Vendredi 12 décembre 2025, toute l'équipe de la matinale de RTL2 s'installe à L'Aronde Riedisheim près de Mulhouse pour une émission exceptionnelle à ne pas manquer. Grégory Ascher, Erika Moulet et toute l'équipe du Double Expresso RTL2 vous ont donné rendez-vous pour une émission spéciale en public et en direct. Les invités du jour - Boulevard des Airs : Le groupe, récompensé par une Victoire de la Musique en 2019, présente son nouvel album "Je rentre à la maison" sorti le 17 octobre 2025. Ils évoquent leur attachement aux racines et leur tournée à venir, qui débutera le 15 janvier à Grenoble et passera par l'Olympia le 18 mars. - Guillaume, potier céramiste : Présent sur le marché de Noël de Mulhouse, il partage sa passion pour la céramique et ses créations uniques, fabriquées à partir d'argile de Dordogne et de Bourgogne. - Sandrine Raymond, responsable de la bibliothèque municipale : Elle parle de la sixième nuit de la lecture sur le thème de Robin des Bois, un événement familial qui désacralise le lieu de la bibliothèque. - Céline de la Biscuiterie Albicère : Elle présente les fameux "Bredala", biscuits traditionnels alsaciens, et parle des ateliers biscuits qu'elle organise. - Solène Roux, directrice adjointe de l'écomusée d'Alsace : Elle décrit le plus grand musée à ciel ouvert de France et ses animations de Noël, notamment le spectacle "Sacrée Lumière". La chanson du jour - Amy Stewart "Knock on Wood" 3 choses à savoir sur Mulhouse - Mulhouse a accueilli Kobe Bryant durant son enfance. - Mulhouse a été un état indépendant jusqu'à la Révolution française. - Le marché de Noël de Mulhouse est solidaire avec une collecte de dons. Le jeu surprise - Nathalie de Mulhouse gagne un séjour au ski à Risoul 1850. La Banque RTL2 - Christophe d'Illzach remporte 1 400 euros. - Nadia de Lille-sur-le-Doux gagne un week-end de détente grâce à Weekend Desk. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

La prise en compte institutionnelle ou simplement relationnelle de la souffrance pose des questions abyssales. Dans cet épisode, je reçois la psychiatre et méditante Patricia Roux-Mérot pour une conversation sur les solutions vraiment sérieuses qui l'ont aidée et qui aident ses patients.Pour vous inscrire au webinaire de présentation de la formation à la méditation proposée par Reso : https://formations.reso.co/webinaire-8-dec-2025/Pour découvrir la formation elle-même : https://formations.reso.co/Mon site : https://www.fabricemidal.comFacebook Fabrice Midal : https://www.facebook.com/FabriceMidalFacebook du podcast Dialogues : https://www.facebook.com/dialogues.fmInstagram Fabrice Midal : https://www.instagram.com/fabricemidalInstagram du podcast Dialogues : https://www.instagram.com/fabricemidal_dialogues/Tiktok : https://www.tiktok.com/@fabricemidalMes trois chaînes YouTube :Mes vidéos : https://www.youtube.com/@fabricemidal1Les Dialogues : https://www.youtube.com/@dialoguesfmLes méditations guidées : https://www.youtube.com/@mediteravecfabricemidalMes podcasts :Le podcast de Fabrice Midal (toutes mes vidéos en version audio) :

Stephan le Roux, bedryfsbestuurder van Amanteco, gesels oor die storie agter Amanteco en die amandelbedryf in Suid-Afrika. Volg RSG Geldsake op Twitter

durée : 00:44:58 - Les Nuits de France Culture - par : Albane Penaranda - Cinquième et dernier volet de la série "Grands savants, grands médecins", cette fiction radiophonique redonne vie à Émile Roux, le très proche et peut-être le plus précieux disciple et collaborateur de Louis Pasteur, un monument de l'histoire scientifique et médicale bien que resté très discret. - réalisation : Rafik Zénine

South of Midnight Part 3: ROUX WAS AHMED BEST?! Square Roots - Episode 488 Quest Log: 0:16:57 Level Up: 1:12:28 Somehow, throughout this series, Jim, Matt and Vanessa never mentioned that the character Roux from Compulsion Games was played by Jar-Jar Binks, everyone's favourite Star Wars character. Or his actor, anyway, Ahmed Best. Also: * Matt and Jim Don't Know Where the Rockstar Headquarters Are * Jim's Famous Matt Character * A Scardey-Cat Fish * Back to the Future is a Christmas Movie * Onlyh Vanessa Knows the Facts of Life Theme This Week: Finish the game! Next Week: Defeat Hooktail in Paper Mario: The Thousand Year Door Our Patreon: http://patreon.com/squarerootspodcast Thanks to Steven Morris for his awesome theme! You can find him at: https://bsky.app/profile/stevenmorrismusic.bsky.social and https://www.youtube.com/user/morrissteven Contact Square Roots! Twitter: @squarerootspod Facebook: https://www.facebook.com/groups/486022898258197/ Email: squarerootspodcast (at) gmail (dort) com

Chez les personnes rousses, la différence ne se limite pas à la couleur flamboyante des cheveux. Elle se joue aussi dans les profondeurs de leur génétique — et jusqu'à la salle d'opération. Depuis une vingtaine d'années, les anesthésistes observent un phénomène fascinant : les roux nécessitent souvent une dose d'anesthésiant plus élevée que la moyenne. En général, entre 10 et 20 % de plus.Pourquoi ? La réponse se cache dans un gène bien particulier : le MC1R.Ce gène, situé sur le chromosome 16, code pour un récepteur impliqué dans la production de mélanine, le pigment qui colore notre peau et nos cheveux. Chez les personnes rousses, une mutation du MC1R empêche ce récepteur de fonctionner normalement. Résultat : le corps fabrique moins d'eumélanine (pigment brun-noir) et davantage de phéomélanine (pigment rouge-orangé). Mais cette mutation n'a pas qu'un effet esthétique : elle influence aussi la chimie du cerveau.Des études menées notamment à l'Université de Louisville et publiées dans Anesthesiology ont montré que cette mutation modifie la sensibilité à certaines substances. Les porteurs de la mutation MC1R seraient plus résistants aux anesthésiques locaux et plus sensibles à la douleur thermique. En d'autres termes, ils ressentent davantage la douleur et répondent moins efficacement à certains analgésiques, comme la lidocaïne ou le desflurane.Les mécanismes exacts ne sont pas encore complètement élucidés, mais tout indique que le gène MC1R interagit indirectement avec les récepteurs opioïdes et les voies dopaminergiques du cerveau, impliqués dans la perception de la douleur. Ce dérèglement explique pourquoi les anesthésistes ajustent leurs doses : ignorer cette particularité pourrait exposer le patient roux à un réveil prématuré ou à une douleur insuffisamment contrôlée pendant l'intervention.Conscients de ces spécificités, de plus en plus de médecins adaptent leur protocole en conséquence, notamment pour les anesthésies générales et locales. Cela ne signifie pas que les roux soient « difficiles à endormir », mais plutôt que leur seuil de réaction diffère.Ainsi, derrière la singularité de leur couleur de cheveux se cache une particularité biologique encore mal connue du grand public : les roux ne sont pas seulement uniques par leur apparence, mais aussi par la manière dont leur organisme réagit à la douleur et aux médicaments destinés à la calmer. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

La Intendencia de Montevideo (IM) inició tareas de reacondicionamiento en la Plaza Matriz de la Ciudad Vieja. Los trabajos incluyen el retiro de arbustos altos de los jardines geométricos, que serán reemplazados por plantas de hasta 70 centímetros. Según la comuna, la medida busca mejorar la visibilidad, la seguridad y el mantenimiento del espacio público. Las plantas retiradas serán trasladadas al vivero municipal para su posterior trasplante. La intervención forma parte del plan de revitalización de Ciudad Vieja. Emiliano Cotelo y Romina Andrioli conversaron con Marcelo Roux, director de Espacios Públicos de la IM.

What is "real" Louisiana cooking? There's Creole, there's Cajun, and what's the difference anyway? However you define it, for many of us, it's simply what your mama used to make that made you feel loved. On this week's show, we meet three Louisiana authors whose cookbooks help tell the authentic story of our state's distinctive cuisine. First, we hear from Eric Cook, the executive chef and owner of two distinguished New Orleans restaurants: Gris-Gris and St. John. Eric talks about the evolution of our traditional local fare – many examples of which can be found in his cookbook, Modern Creole: A Taste of New Orleans Culture and Cuisine. Eric shares his secrets to success with dishes such as crab and shrimp stew, wild duck cassoulet, and even his mama's chicken and dumplings. Next, we welcome food writer and culinary historian Marcelle Bienvenu, who has reported on Cajun and Creole cooking for half a century. She shares her expert knowledge and talks about the fifth edition of her classic cookbook, Who's Your Mama, Are You Catholic, and Can You Make a Roux? Finally, for 125 years, Vaucresson Sausage Company has produced its beloved brand in New Orleans' Seventh Ward. In her debut cookbook, Creole Made Easy, co-owner Julie Vaucresson shares recipes and stories both from her illustrious family of origin and the family she married into. For more of all things Louisiana Eats, be sure to visit us at PoppyTooker.com.

Entrevista Marcelo Roux - Director de Espacios Públicos by En Perspectiva

China se groeiende aptyt vir Namibiese beesvleis kan die vraag tot 20 000 ton per maand laat styg, maar kenners waarsku dat produksie nie tred sal kan hou nie. In 'n onderhoud met Kosmos 94.1 Nuus het landboukenner Wallie Roux gesê Namibië, die droogste Afrika-land suid van die Sahara, staar natuurlike beperkings in die gesig ten opsigte van hoeveel dit kan produseer. Die land se afhanklikheid van reënval beteken dat die uitbreiding van beesvleisproduksie met stygende koste sal gepaardgaan. Roux het meer.

Education activist Vanessa le Roux chats to John Maytham about the victim of bullying at Milnerton High School, and the steps being taken to get justice for the learner Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

This week, it's all smoke and discipline with the pitmaster–entrepreneur himself, Chef Charlie Mckenna. He's the founder behind Lillie's Q, known for Memphis in May-winning pork shoulder, as well as his regionally faithful Lillie's Q sauces and rubs. He tells us about the journey from CIA grad and Michelin-line cook to Chicago barbecue, and what his Air Force family's “six Ps” instilled in his leadership. Plus: how CPG realities differ from fine dining, how Roux lets him serve his favorite dishes, the secret salsa at Tony's Burrito Mex, and so much more!

Her name is Paige Roux, but you may know her as Some Chick Who Shoots!  Paige is a nationally recognized firearms instructor for women and she empowers first-time gun owners to feel confident, safe, and prepared.  She joins us to share not only her personal journey and passions, but also to discuss a wide variety of topics surrounding gun ownership, firearm safety, learning to shoot, 2nd Amendment advocacy and more!  Paige provides valuable insight and perspectives for not just female gun owners, but also within family dynamics and preserving safe firearm practices in the home. This episode breaks the mold of our normal show by tapping into another important genre of self-defense and our right to bear arms!Fall Obsession Podcast is sponsored by:Hoot Camo Company (https://hootcamo.com/)Bear River Archery (https://www.bearriverarchery.com/)Trophy Edits (https://trophyedits.com/?ref=fallobsession)The Outdoor Call Radio App (https://www.theoutdoorcallradio.com/)

Sleeve, bypass, or something new – which surgery really dominates the day?  This Bariatric Surgery Journal Club dives into the debate over which bariatric operation is best. We compare the outcomes of the gastric bypass, sleeve gastrectomy, and the newer Sadie procedure, exploring how bypass may have an edge in long-term diabetes remission and weight loss.  We also discuss revisional options for failed sleeves and the importance of matching the patient to the right operation for their specific needs. Hosts: - Matthew Martin, trauma and bariatric surgeon at the University of Southern California/Los Angeles General Medical Center (Los Angeles, California)  - Adrian Dan, bariatric and MIS surgeon, program director for the advanced MIS bariatric and foregut fellowship at Summa Health System (Akron, Ohio) - Crystal Johnson Mann, bariatric and foregut surgeon at the University of Florida (Gainesville, Florida) - Katherine Cironi, general surgery resident at the University of Southern California/Los Angeles General Medical Center (Los Angeles, California) Learning objectives: - Contrast the outcomes of Roux-en-Y gastric bypass, sleeve gastrectomy, and revisional options such as the single-anastomosis duodeno-ileal bypass (SADI) - Article #1: Hauge 2025, Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple blind, randomized controlled trial https://pubmed.ncbi.nlm.nih.gov/40185112/ - Describe the design and unique triple-blind methodology of a single-center randomized trial comparing bypass and sleeve in patients with obesity and type 2 diabetes.  - Interpret the clinical relevance of the 5-year outcomes, including 63% diabetes remission with bypass vs 30% with sleeve.  - Examine secondary outcomes such as weight loss and cholesterol reduction, which favored bypass over the sleeve - Formulate patient-centered strategies for selecting bypass versus sleeve in populations with advanced metabolic disease, balancing efficacy with patient preference  - Article #2: The By-Band-Sleeve Collaborative Group 2025, Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicenter, open-label, three-group, randomized controlled trial https://pubmed.ncbi.nlm.nih.gov/40179925/ - Summarize the findings of this multi-center, open-label randomized controlled trial of over 1,300 patients comparing bypass, sleeve, and gastric banding at 5 years - Discuss the relative weight loss outcomes: 67% excess weight loss for bypass, 63% for sleeve, and 28% for adjustable gastric band - Evaluate the improvements in diabetes remission, hypertension control, and lipid management with bypass and sleeve compared to banding. - Analyze the declining role of gastric banding in modern bariatric surgery, while acknowledging its benefits compared to no weight loss treatment - Article #3: Thomopoulos 2024, Long-term results of Roux-en-Y gastric bypass (RYGB) versus single anastomosis duodeno-ileal bypass (SADI) as revisional procedures after failed sleeve gastrectomy: a systematic literature review and pooled analysis https://pubmed.ncbi.nlm.nih.gov/39579238/ - Compare long-term outcomes of bypass versus SADI after failed sleeve gastrectomy, based on pooled analysis of over 1,000 patients  - Interpret the trade-offs: SADI provides greater weight loss and metabolic improvements, but carries a higher risk for malnutrition and fat-soluble vitamin deficiencies  -  Develop strategies for preoperative counseling, nutritional supplementation, and close long-term monitoring, particularly for patients undergoing SADI - Individualize decision-making for revisional surgery, considering factors such as patient goals, comorbidity burden, prior anatomy, BMI, and reliability with follow-up - Evolving revisional strategies will influence the next decade of bariatric surgical innovation   - Overall, bariatric surgery consistently improves weight, diabetes control, and cardiovascular risk. - The procedure of choice should be tailored to the patient through detailed discussion between surgeon and patient, aligning clinical evidence with patient goals and risks.   References 1.     Wågen Hauge J, Borgeraas H, Birkeland KI, Johnson LK, Hertel JK, Hagen M, Gulseth HL, Lindberg M, Lorentzen J, Seip B, Kolotkin RL, Svanevik M, Valderhaug TG, Sandbu R, Hjelmesæth J, Hofsø D. Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2025 May;13(5):397-409. doi: 10.1016/S2213-8587(24)00396-6. Epub 2025 Apr 1. PMID: 40185112. https://pubmed.ncbi.nlm.nih.gov/40185112/ 2.     By-Band-Sleeve Collaborative Group. Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicentre, open label, three-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2025 May;13(5):410-426. doi: 10.1016/S2213-8587(25)00025-7. Epub 2025 Mar 31. PMID: 40179925. https://pubmed.ncbi.nlm.nih.gov/40179925/ 3.     Thomopoulos T, Mantziari S, Joliat GR. Long-term results of Roux-en-Y gastric bypass (RYGB) versus single anastomosis duodeno-ileal bypass (SADI) as revisional procedures after failed sleeve gastrectomy: a systematic literature review and pooled analysis. Langenbecks Arch Surg. 2024 Nov 23;409(1):354. doi: 10.1007/s00423-024-03557-9. PMID: 39579238; PMCID: PMC11585492. https://pubmed.ncbi.nlm.nih.gov/39579238/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Dr. Cecil Wood discusses the RadioGraphics article “Internal Hernias after Roux-en-Y Gastric Bypass: Clues to a Challenging Diagnosis”, highlighting why these complex and potentially dangerous complications remain difficult to identify. He explains surgical anatomy, risk factors, and key CT signs, offering a systematic approach to improve diagnostic accuracy for radiologists. Internal Hernias after Roux-en-Y Gastric Bypass:Clues to a Challenging Diagnosis. Wood et al. RadioGraphics 2025; 45(10):e240197.